one health Archives - ELIAS Animal Health

Pet Cancer Awareness Month and the One Health Connection

Pets bring us immense joy and companionship, making them cherished members of our families. However, just like humans, they too can be affected by cancer. Pet Cancer Awareness Month, observed throughout November, is a reminder of the importance of early detection, prevention, and treatment of cancer in our animal companions. Fittingly, it coincides with One Health Day on November 3, which emphasizes the interconnectedness of human and animal health, and the environment we share. Cancer Can Happen to Pets Too Cancer is a complex and devastating disease that can affect any breed, age, or species of pet. Just like in humans, pet cancer occurs when abnormal cells grow uncontrollably, forming tumors that can spread to other parts of the body. The most common types of cancer found in dogs include lymphoma, mast cell tumors, and osteosarcoma (bone cancer), while cats are often prone to lymphoma, mammary cancer, and oral cancers. [...]

One Health: Leveraging the Intersection of Health Across Our World

January is One Health Awareness Month, which recognizes and promotes the "interconnectedness of the health of people, animals, and the environment." (Forbes.) ELIAS Animal Health was founded to apply the progress that has been made in fighting human cancers in the veterinary space, and then share the findings with our human health counterparts. We follow a collaborative, interdisciplinary approach, aligned with the One Health philosophy about the connections and correlations between the health of people, animals, and the environment. Human and canine cancers share similarities, so research on either side can impact and support the other: TVAX Biomedical is launching a glioblastoma study in the near future. ELIAS’ origins came from the early work and research conducted by TVAX. TVAX and Genelux Corporation, a clinical stage immunotherapy company focused on developing oncolytic virus therapies for humans, have formed a joint venture known as V2ACT Therapeutics™, LLC that will focus on [...]